European Organisation for Research and Treatment of Cancer

Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer

Retrieved on: 
Wednesday, November 8, 2023

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be used in a new breast cancer study called TREAT ctDNA (EORTC 2129-BCG).

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be used in a new breast cancer study called TREAT ctDNA (EORTC 2129-BCG).
  • This international, multi-center, randomized, phase III clinical trial is being conducted by the European Organisation for Research and Treatment of Cancer (EORTC) Breast Cancer Group in collaboration with Natera and Menarini Group (Menarini), a leading international pharmaceutical and diagnostics company.
  • “We are excited to offer to our high-risk, ctDNA positive, ER+/HER2- early-stage breast cancer patients the possibility to participate in the TREAT ctDNA trial.
  • “Collaborations with leading clinical trial organizations like EORTC are needed as we seek to demonstrate the power of treatment on molecular recurrence across cancer indications.

Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 7, 2023

& ROCKVILLE, Md., US, 07 November 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.

Key Points: 
  • & ROCKVILLE, Md., US, 07 November 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announced its financial results for the third quarter ended September 30, 2023, and provided a business update.
  • Commercial sales have increased in the United States and European countries, including France, Germany and Italy, during the third quarter.
  • Since the beginning of 2023, we have launched KIMMTRAK in Austria, Israel, Italy, Finland, Switzerland and Belgium, and have recently reached price agreements with Canada and Australia.
  • Cash and cash equivalents were £364.0 million ($444.5 million) as of September 30, 2023, compared to £332.5 million as of December 31, 2022.

European Organisation for Research and Treatment of Cancer & the Menarini Group Launch New Clinical Trial in Early-Stage Breast Cancer

Retrieved on: 
Thursday, October 19, 2023

A molecular residual disease (MRD) test for the detection of circulating tumour DNA (ctDNA) will also be used.

Key Points: 
  • A molecular residual disease (MRD) test for the detection of circulating tumour DNA (ctDNA) will also be used.
  • The study was submitted under the new Clinical Trial Regulation, and it is expected to start the activation process in the fourth quarter of 2023.
  • "We are excited to offer to our high-risk, ctDNA positive, ER+/HER2- early-stage breast cancer patients the possibility to participate in the Treat ctDNA trial.
  • This intergroup trial, managed by the EORTC Breast Cancer Group, will be jointly conducted with several national and international cancer clinical research groups, including the German SUCCESS group under the umbrella of BIG (Breast International Group).

SK Biopharmaceuticals’ Proteovant Therapeutics Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Thursday, October 12, 2023

Findings are being presented today at the American Association for Cancer Research (AACR), National Cancer Institute (NCI), and the European Organisation for Research and Treatment (EORTC) International Conference on Molecular Targets and Cancer Therapeutics being held in Boston.

Key Points: 
  • Findings are being presented today at the American Association for Cancer Research (AACR), National Cancer Institute (NCI), and the European Organisation for Research and Treatment (EORTC) International Conference on Molecular Targets and Cancer Therapeutics being held in Boston.
  • The AACR-NCI-EORTC Conference attracts researchers from around the world to discuss innovations in drug development, target selection, the impact of new discoveries in cellular and molecular biology, and early clinical trials.
  • Today’s presentation is the second in a series of important meetings at which the Proteovant team is sharing research findings that show potential best- and first-in-class protein degraders.
  • “Although strategies targeting androgen receptor in the treatment of prostate cancer have shown benefits for patients, the reality is that cancer cells ultimately find ways to bypass these therapies, resulting in disease progression," said Zhihua Sui, Ph.D. Chief Scientific Officer, Proteovant Therapeutics.

Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Saturday, October 14, 2023

Aberrant MET oncogenic alterations include: MET exon 14 skipping (MET∆ex14) mutations; activating mutations in the kinase domain; MET gene amplification; MET fusions; and MET protein overexpression.

Key Points: 
  • Aberrant MET oncogenic alterations include: MET exon 14 skipping (MET∆ex14) mutations; activating mutations in the kinase domain; MET gene amplification; MET fusions; and MET protein overexpression.
  • Presently, type I c-Met inhibitors such as Capmatinib are used as monotherapies in patients with locally advanced or metastatic NSCLC with MET∆ex14 mutations.
  • However, development of post-treatment resistance to type I c-Met inhibitors occurs clinically, including through acquired mutations in codons D1228 and Y1230.
  • Next generation MET inhibitors are thus needed to treat patients harboring various MET oncogenic alterations beyond MET∆ex14, including post-treatment acquired mutations.

Scorpion Therapeutics Presents Preclinical Data for STX-241, a Fourth-Generation EGFR Inhibitor, at the AACR-NCI-EORTC Symposium 2023

Retrieved on: 
Friday, October 13, 2023

The data will be presented today in a poster session at the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer (“AACR-NCI-EORTC”) Symposium 2023 in Boston, Massachusetts.

Key Points: 
  • The data will be presented today in a poster session at the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer (“AACR-NCI-EORTC”) Symposium 2023 in Boston, Massachusetts.
  • There are currently no approved therapeutic options for patients that develop “double mutant” EGFR NSCLC.
  • “We designed STX-241 as a potentially best-in-class small molecule for NSCLC patients who progress following first-line therapy,” said Darrin Stuart, Ph.D., Chief Scientific Officer of Scorpion Therapeutics.
  • Scorpion is also developing STX-721, a potentially best-in-class exon 20 mutant EGFR inhibitor, which entered the clinic earlier this month.

Promontory Therapeutics Presents Data on the Molecular Effects of PT-112 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Saturday, October 14, 2023

NEW YORK, Oct. 14, 2023 /PRNewswire/ -- Promontory Therapeutics Inc., a clinical stage biotech company advancing immunogenic small molecule approaches in oncology, today presented data on its lead therapeutic candidate PT-112, detailing its early molecular effects that culminate in immunogenic cancer cell death (ICD). The presentation was made at the American Association for Cancer Research (AACR) – National Cancer Institute (NCI) – European Organisation for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston.

Key Points: 
  • The presentation was made at the American Association for Cancer Research (AACR) – National Cancer Institute (NCI) – European Organisation for Research and Treatment of Cancer (EORTC) International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023 in Boston.
  • Researchers also conducted nascent RNA sequencing in human cancer cells (non-small cell lung, prostate and renal cell carcinoma) following one and six hours of PT-112 treatment.
  • "While further validation of these findings is ongoing, this work deepens our understanding of PT-112's specific molecular effects.
  • PT-112 rapidly causes ribosomal biogenesis (RiBi) inhibition and nucleolar stress, likely driving previously observed PT-112-induced cancer organelle stresses and ICD.

SK Biopharmaceuticals' Proteovant Therapeutics Presents Preclinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Friday, October 13, 2023

SEOUL, South Korea and KING OF PRUSSIA, Pa., Oct. 12, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global biotech focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS) and oncology, and its U.S. R&D subsidiary, Proteovant Therapeutics, presented data showing that selectively degrading the epigenetic protein p300, with minimal impact on its paralog CBP, results in suppression of androgen receptor signaling and inhibition of tumor growth in a mouse model of androgen receptor (AR) positive prostate cancer. Findings are being presented today at the American Association for Cancer Research (AACR), National Cancer Institute (NCI), and the European Organisation for Research and Treatment (EORTC) International Conference on Molecular Targets and Cancer Therapeutics being held in Boston.

Key Points: 
  • Findings are being presented today at the American Association for Cancer Research (AACR), National Cancer Institute (NCI), and the European Organisation for Research and Treatment (EORTC) International Conference on Molecular Targets and Cancer Therapeutics being held in Boston.
  • The AACR-NCI-EORTC Conference attracts researchers from around the world to discuss innovations in drug development, target selection, the impact of new discoveries in cellular and molecular biology, and early clinical trials.
  • "These data showcase a first-in-class opportunity for therapeutic intervention that suppresses AR signaling through an androgen-independent mechanism."
  • "We are excited about what our Proteovant team is doing to find novel approaches to treat metastatic castration-resistant prostate cancer," Donghoon Lee, President and CEO of SK Biopharmaceuticals and SK Life Science.

Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference

Retrieved on: 
Wednesday, October 4, 2023

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced a poster presentation at the upcoming 2023 International Conference on Molecular Targets and Cancer Therapeutics hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer to be held in Boston from October 11-15, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced a poster presentation at the upcoming 2023 International Conference on Molecular Targets and Cancer Therapeutics hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer to be held in Boston from October 11-15, 2023.
  • Details of the poster presentation is as follows:

Kyowa Kirin Demonstrates Commitment to Real-world Evidence for POTELIGEO® (mogamulizumab) at EORTC 2023.

Retrieved on: 
Thursday, September 21, 2023

Danie du Plessis, Executive Vice President of International Medical Affairs, Kyowa Kirin, commented: “The studies presented at EORTC-CLTG demonstrate our long-term commitment to expand the evidence base for the effectiveness of mogamulizumab in real-world settings.

Key Points: 
  • Danie du Plessis, Executive Vice President of International Medical Affairs, Kyowa Kirin, commented: “The studies presented at EORTC-CLTG demonstrate our long-term commitment to expand the evidence base for the effectiveness of mogamulizumab in real-world settings.
  • OMEGA, a completed, retrospective, real-world, non-interventional observational study, described real-world effectiveness and tolerability of mogamulizumab in patients with MF and SS.
  • Across all three trials no new safety signals were seen.
  • The real-world evidence being generated by Kyowa Kirin raises the standard of information available to those involved in treating mycosis fungoides and Sézary syndrome helping to inform decisions that support optimal patient care.”